Phase 3 Readout~month

Phase 3 Topline: A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801

Indication
Melanoma (Skin Cancer); Melanoma Stage IIIB-IV; Cutaneous Melanoma

Other upcoming events for HRTX

Phase 3 ReadoutPhase 3 Topline: A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801
Patent ExpiryPatent/Exclusivity Expiry: AKYNZEO
Patent ExpiryPatent/Exclusivity Expiry: FOCINVEZ

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 — HRTX Phase 3 Readout | BioSniper